Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Catalyst Pharmaceuticals Inc.
Headquarters: Coral Gables, FL, United States of America
Website: http://www.catalystpharma.com...
Year Founded: 2002
Status: Public
Industry Sector: HealthTechnology
CEO: Richard John Daly, MBA
Number Of Employees: 181
Enterprise Value: $2,093,207,995
PE Ratio: 18.42
Exchange/Ticker 1: NASDAQ:CPRX
Exchange/Ticker 2: N/A
Latest Market Cap: $2,928,159,488
BioCentury | Mar 12, 2025
Politics, Policy & Law
House spending bill omits PRV reauthorization, slashes biomedical research program
Fate of continuing resolution in doubt as Senate Democrats balk ahead of Friday deadline to avert government shutdown
BioCentury | Jul 2, 2024
Politics, Policy & Law
Sen. Cassidy calls for FDA to adapt to post-Chevron world
Ranking HELP member says no cause for alarm, but agency should reconsider LDT, orphan exclusivity policies
BioCentury | Jun 28, 2024
Politics, Policy & Law
Clearest impacts of Chevron ruling will be on disputes over exclusivity, other non-science issues
Broad effect of Supreme Court decision on science-based regulation unclear
BioCentury | Jan 5, 2024
Finance
Catalysts drive follow-ons for Dyne, Longboard, Voyager in first week of 2024
Seven NASDAQ-listed biotechs together raise more than $1.6B in year’s first days, with Arrowhead drawing the largest amount
BioCentury | Dec 19, 2023
Deals
Dec. 18 Quick Takes: Illumina to divest Grail
Plus: Pivotal closes $389M Partners Fund II and updates from Novo Nordisk Foundation, Mirum, Santhera, Arcutis and Checkpoint
BioCentury | Dec 6, 2023
Management Tracks
Catalyst hires Michael Kalb as CFO
Plus: Raab to become Amicus chair when Crowley heads to BIO and updates from AC Immune, Gossamer Bio, Chimerix, Versameb, Alzheon, Kling and Avalere
BioCentury | Nov 14, 2023
Data Byte
The six new drugs FDA approved in October
Autoimmune disease therapies accounted for four of FDA’s six NME approvals last month
BioCentury | Oct 27, 2023
Data Byte
Where FDA, EMA do and don’t agree in neurology
FDA has granted accelerated approval to seven neuroscience NMEs since 2016, none of which are approved in Europe
BioCentury | Oct 27, 2023
Finance
Oct. 26 Quick Takes: Triveni raises $92M for genetics-driven immunology pipeline
Plus: Sofinnova Partners closes digital medicine fund with $200M and more from BMS, Santhera and ImmunityBio
BioCentury | Oct 21, 2023
Management Tracks
Daly to succeed McEnany as Catalyst CEO
Plus: Hennemand joins Covant as CEO and updates from Invitae, Immunome, Antiva, Omeros, Actimed and RegCell
Items per page:
1 - 10 of 60